by Small scale bioreactors play a vital role in pharmaceutical, biotechnology and life science research by enabling small-scale cell culture production and experiments. Small scale bioreactors are benchtop instruments that can process small cell culture volumes from milliliters to tens of liters. They offer advantages like cost-effectiveness, minimal contamination risk and ease of operation compared to large-scale bioreactors. Small scale bioreactors are used in various applications like process development, quality control testing and pilot studies.
The Global Small Scale Bioreactors Market Demand is estimated to be valued at US$ 1738.21 Mn in 2024 and is expected to exhibit a CAGR of 3.8% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Small Scale Bioreactors are LabCorp, Quest Diagnostics, Abbott Laboratories, Bio-Rad Laboratories, Inc., bioMérieux SA, DiaSorin S.p.A, T2 Biosystems, Inc., F. Hoffmann-La Roche AG, Meridian Bioscience, Inc., Quidel Corporation, and Thermo Fisher Scientific Inc. The growing demand for miniature bioprocessing equipment from research laboratories and biopharmaceutical companies is expected to propel the small scale bioreactors market. With growing biologics outsourcing and rising demand in Asia Pacific and Europe, key players are expanding their global footprint to tap the market potential.
Market key trends
The small scale bioreactors market is increasingly adopting single-use technologies over stainless steel bioreactors due to advantages like flexibility, reduced contamination risk and lower capital costs. Single-use bioreactors are seeing rising adoption as they enable faster development timelines, require less validation and facilitate global expansion of biopharma companies. While stainless steel vessels still dominate the industry, the trend towards disposable single-use technologies is poised to surge the small scale bioreactors market over the forecast period.
Porter’s Analysis
Threat of new entrants: High setup costs like facility establishment and R&D acts as a barrier.
Bargaining power of buyers: Buyers have moderate bargaining power as they have a few alternatives in the market.
Bargaining power of suppliers: Suppliers have high bargaining power due to their technical expertise and proprietary bioprocessing technologies.
Threat of new substitutes: Low threat as bioreactors are unique laboratory equipment with no close substitute.
Competitive rivalry: Intense as key players compete on product quality, price, and innovation.
Geographical Regions
North America dominated the market in terms of value in 2024 due to increased support for cell-based research in the US and Canada. Presence of major biopharma companies and expanding biotech industry drive regional growth.
Asia Pacific is poised to be the fastest growing region during the forecast period owing to rising biologics production in China, India, and South Korea coupled with growing R&D investment by pharmaceutical companies in the region. Increase in contract research and manufacturing activities boost the regional market.
